Please select the eligibility criteria that correspond to the clinical trial below.
Title: A Phase III, Randomized, Multicentre Trial Comparing Allogeneic Filgrastim Mobilised Peripheral Blood Progenitor Cell Transplantation (PBPCT) With Allogeneic Bone Marrow Transplantation (BMT) in Patients With Acute Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Brief Summary: 350 patients with early leukemias were assigned to receive peripheral blood or bone marrow transplantation; the occurrence of acute and chronic graft versus host disease, survival, transplantation-related mortality, and relapse rates were compared.


Options:
A: Inclusion Criteria:

* Patients with either diagnosis of AML in first or second remission, in first untreated relapse (blast count in marrow \< 30%); ALL in first or second remission, in first untreated relapse (blast count in marrow \< 30%); CML in first chronic phase, in first accelerated phase (total blast and promyelocytes in marrow and or peripheral blood \< 30%) or MDS (excluding RAEB-t).
* Age between 18 and 55 years.
* ECOG performance status between 0,1 or 2.
* HLA-identical sibling donor.
* Written informed consent.

Exclusion Criteria:

* Serum creatinine more than 10% above the normal range for the centre.
* Left ventricular size and function abnormal.
* DLCO \< 50%.
* Bilirubin \> 2mg/dL (34.2 µmol/L).
* Splenectomised or splenic irradiation.
* Psychiatric, addictive, or any other disorder, which compromises ability to give truly informed consent for participation in this study.
* Currently receiving non-licensed drugs which may affect GVHD or engraftment.
* Pregnant or lactating women.
* Known sensitivity to E.coli derived products.
* HIV positive.
* Previously received BM/PBPC transplant.
B: Inclusion Criteria:

* Eligible for this study were patients diagnosed with HNC, older than 18 years and able to read and write Swedish and, in addition, suitable for outpatient treatment with chemo- and/or radiotherapy, either as primary treatment or in a postoperative setting.

Exclusion Criteria:

* Patients were excluded if they had a previous or concomitant malignancy or were diagnosed and treated for depression as stated in their medical record.
* In order to minimize the risk of bias, none of the patients were to be included if they were taking part in other research studies
C: Inclusion Criteria:

* patients in acute care for cancer
* written informed consent
* 18 years and older
* ability to complete questionnaires

Exclusion Criteria:

- insufficient command of German
D: Inclusion Criteria:

* Age ≥ 21
* Diagnosis of breast cancer, Stage III, IV, or Stage I or II with metastasis or recurrence
* Able to perform basic ADLs
* Undergoing chemotherapy and/or hormonal therapy for breast cancer
* Able to speak and understand English
* Have access to a telephone
* Able to hear normal conversation
* Cognitively oriented to time, place, and person (determined via nurse recruiter)

Exclusion Criteria:

* Diagnosis of major mental illness on the medical record and verified by the recruiter
* Residing in a nursing home
* Bedridden
* Currently receiving regular reflexology
* Diagnosis of symptoms of deep vein thrombosis or painful foot neuropathy, which will require medical approval

Answer: A